Stability and compatibility of hydromorphone hydrochloride in an implantable infusion system

27Citations
Citations of this article
20Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

With the exception of morphine, hydromorphone is the most commonly used intrathecal opioid for the treatment of intractable pain. The purpose of this study was to evaluate the stability and compatibility of hydromorphone in the implantable infusion system that is most commonly used in these patients. Hydromorphone solution was incubated at 37°C in infusion system reservoirs and with individual materials which comprise the fluid pathway of the infusion system. Stability was analyzed using high performance liquid chromatography; mechanical integrity of device materials was evaluated after drug exposure. After 4 months of exposure to device materials or intact devices, hydromorphone concentration remained greater than 95% of starting material. All device materials retained acceptable mechanical performance. These results demonstrate that hydromorphone is stable at physiological temperatures for at least 4 months in an implantable infusion system and that current clinical practice of refilling the pump every 3 months is appropriate. © U.S. Cancer Pain Relief Committee, 2001.

Cite

CITATION STYLE

APA

Hildebrand, K. R., Elsberry, D. E., & Anderson, V. C. (2001). Stability and compatibility of hydromorphone hydrochloride in an implantable infusion system. Journal of Pain and Symptom Management, 22(6), 1042–1047. https://doi.org/10.1016/S0885-3924(01)00364-5

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free